



## PerkinElmer Announces New Subsidiary to Distribute & Service Instrumentation in Ireland

WALTHAM, Mass. – PerkinElmer Life and Analytical Sciences, a global leader in Health Sciences and Photonics, today announced that it will begin direct distribution of its instrumentation and extend its suite of services, including its portfolio of OneSource® solutions, in the Republic of Ireland and Northern Ireland.

The new PerkinElmer subsidiary, PerkinElmer Ireland Ltd., will assume direct responsibility for instrumentation sales, service and support for more than 250 customers in Ireland from its distributor, Foss Ireland Ltd. This move reinforces PerkinElmer's commitment to provide its customers with many of the industry's most innovative products and services while providing a greater level of support for customers in a wide range of markets including pharmaceutical, biotech, and government and private research laboratories.

“Bringing a seamless product and service solution to our customers in Ireland will enable them to fully reap the benefit of PerkinElmer's proven expertise globally to meet both scientific and business needs and improve laboratory performance,” said Robert F. Friel, President and Chief Executive Officer, PerkinElmer.

For more information, visit [www.perkinelmer.com](http://www.perkinelmer.com).

### Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of \$1.8 billion in 2007, has 9,100 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through [www.perkinelmer.com](http://www.perkinelmer.com) or 1-877-PKI-NYSE.

For further information regarding PerkinElmer, please contact:

Media Contact:

Ellen Wein

(412) 456-0986

or

Lesley Sillaman Lesley Sillaman

(412) 456-7839